Drug Companies Withdraw PARPi Indications for Ovarian Cancer Drug Companies Withdraw PARPi Indications for Ovarian Cancer

Zejula, Lynparza, and Rubraca have been voluntarily withdrawn for late-line ovarian cancer treatment indications over concerns surrounding an increased risk for death.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news